

Double/Triple Hit
Myc Negative
Myc+;NoDBTPHit
Myc+;DBTPHit
Events,n Median (95% CI)
Myc Negative (n=38) 19 6.2 (2.9-NA)
Myc +;NoDBTPHit (n=50) 33 2.8 (1.1-9)
Myc+;DBTPHit (n=20) 15 2.1 (0.79-2.5)
Probability
1.00
0.75
0.50
0.25
0.00
0 3 6 9 12 15 18 21 24
Months Post CTL019 Infusion
Number at risk
Double/Triple Hit
Myc Negative 38 22 19 17 15 15 15 14 5
Myc+;NoDBTPHit 50 18 14 14 10 10 8 6 4
Myc+;DBTPHit 20 4 3 3 2 2 2 1 0
0 3 6 9 12 15 18 21 24
Months Post CTL019 Infusion

FIG. 1A



Double/Triple Hit
Myc Negative
Myc+;NoDBTPHit
Myc+;DBTPHit
Events,n Median (95% CI)
Myc Negative (n=38) 19 21 (10-NA)
Myc +;NoDBTPHit (n=50) 27 13 (5.5-NA)
Myc+;DBTPHit (n=20) 16 3.8 (1.9-12)
Probability
1.00
0.75
0.50
0.25
0.00
0 3 6 9 12 15 18 21 24 27 30
Months Post CTL019 Infusion
Number at risk
Double/Triple Hit
Myc Negative 38 32 27 25 21 19 18 17 12 8 5
Myc+;NoDBTPHit 50 42 29 24 19 17 17 16 10 5 1
Myc+;DBTPHit 20 12 8 7 5 5 4 3 1 1 0
0 3 6 9 12 15 18 21 24 27 30
Months Post CTL019 Infusion

FIG. 1B



PFS1 Analysis by Double/Triple Hit
Double/Triple Hit
Myc(-)/NoDBTPHit
Myc+;DBTPHit
1.00
0.75
0.50
0.25
0.00
Probability
p = 0.022
0
3
6
9
12
15
18
21
24
Months Post CTL019 Infusion
Number at risk
Double/Triple Hit
Myc(-)/NoDBTPHit 91 42 34 32 26 26 24 21 9
Myc+;DBTPHit 20 4 3 3 2 2 2 1 0
0
3
6
9
12
15
18
21
24
Months Post CTL019 Infusion

FIG. 2A



OS Analysis by Double/Triple Hit
Double/Triple Hit
Myc(-)/NoDBTPHit
Myc+;DBTPHit
1.00
0.75
0.50
0.25
0.00
Probability
p = 0.0049
0 3 6 9 12 15 18 21 24 27 30
Months Post CTL019 Infusion
Number at risk
Myc(-)/NoDBTPHit 91 77 58 50 41 37 36 34 23 14 6
Myc+;DBTPHit 20 12 8 7 5 5 4 3 1 1 0
0 3 6 9 12 15 18 21 24 27 30
Months Post CTL019 Infusion

FIG. 2B



DOR Analysis by Double/Triple Hit
Double/Triple Hit
Myc Negative
Myc+;NoDBTPHit
Myc+;DBTPHit
Probability
1.00
0.75
0.50
0.25
0.00
p = 0.023
0
3
6
9
12
15
18
21
24
Months Post CTL019 Infusion
Number at risk
Double/Triple Hit
Myc Negative 24 20 19 17 15 15 15 14 5
Myc+;NoDBTPHit 25 19 15 15 11 11 8 7 4
Myc+;DBTPHit 8 4 3 3 2 2 2 1 0
0 3 6 9 12 15 18 21 24
Months Post CTL019 Infusion

FIG. 3A



DOR Analysis by Double/Triple Hit
Double/Triple Hit
Myc(-)/NoDBTPHit
Myc+;DBTPHit
Probability
1.00
0.75
0.50
0.25
0.00
p = 0.017
0
3
6
9
12
15
18
21
24
Months Post CTL019 Infusion
Number at risk
Double/Triple Hit
Myc(-)/NoDBTPHit 49 39 34 32 26 26 23 21 9
Myc+;DBTPHit 8 4 3 3 2 2 2 1 0
0
3
6
9
12
15
18
21
24
Months Post CTL019 Infusion

FIG. 3B



DOR
C2201 DOR1 Analysis by Myc in Baseline Tumor Biopsy
Myc Status
Negative
Positive
Probability of maintaining response, %
1.00
0.75
0.50
0.25
0.00
Events, n
Median (95% CI)
Negative (n=24)
5
NA (NA-NA)
Positive (n=33)
15
19 (3.4-NA)
p = 0.039
0 3 6 9 12 15 18 21 24 27 30 33 36 39
Time since infusion, mo
Number at Risk
Negative 24 19 17 17 16 16 14 13 11 11 10 9 3 0
Positive 33 21 16 15 13 11 11 10 8 8 8 7 1 1

FIG. 4A



PFS
C2201 PFS Analysis by Myc in Baseline Tumor Biopsy
Myc Status
Negative
Positive
Events, n
Median (95% CI)
Negative (n=38)
20
6.2 (2.9-NA)
Positive (n=73)
49
2.5 (1.7-3)
Probability of PFS, %
1.00
0.75
0.50
0.25
0.00
p = 0.0093
0 3 6 9 12 15 18 21 24 27 30 33 36 39
Time since infusion, mo
Number at Risk
Negative 38 22 19 17 16 16 16 14 13 11 11 11 5 0
Positive 73 23 17 17 13 13 12 10 9 8 8 8 5 1

FIG. 4B



OS
C2201 OS Analysis by Myc in Baseline Tumor Biopsy
Myc Status
Negative
Positive
Events, n
Median (95% CI)
Negative (n=38)
21
21(10-NA)
Positive (n=73)
47
7.8 (4.6-18)
Probability of survival, %
1.00
0.75
0.50
0.25
0.00
p = 0.12
0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48
Time since infusion, mo
Number at Risk
Negative 38 32 27 25 22 20 20 19 18 17 16 16 14 10 6 2 0
Positive 73 57 39 32 27 25 24 22 21 19 17 16 15 7 3 2 1

FIG. 4C

Subgroup Analysis of BOR by Baseline Variables
Subgroups for BOR
No. of Pats
No. of CR.PR
ORR (95% CI)
Fisher.exact.p.val
Overall
115
60
52% (43% - 62%)
Disease Subtypes
0.06
Diffuse Large B-Cell Lymphoma
92
44
48% (37% - 58%)
Transformed follicular lymphoma
21
15
71% (48% - 89%)
Molecular Subtypes
0.45
activated B—cell (ABC)
49
27
55% (40% - 69%)
germinal center (GC)
63
30
48% (35% - 61%)
CD19 Expression
0.51
CD19.No.Low
30
17
57% (37% - 75%)
CD19.POS
62
30
48% (35% - 61%)
C-Myc by IHC
0.07
Negative
38
24
63% (46% - 78%)
Positive
73
32
44% (32% - 56%)
MYC/BCL2/BCL6 Rearrangement
0.33
Double/Triple hits
20
8
40% (19% - 64%)
Negative/Not Done
91
49
54% (43% - 64%)
MYC/BCL2/BCL6 Rearrangement
0.24
Double/Triple hits
20
8
40% (19% - 64%)
Negative
52
25
48% (34% - 62%)
Not Done
39
24
62% (45% - 77%)
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1

FIG. 5



Subgroup Analysis of M6 Response by Baseline Variables
Subgroups for RSPM6
No. of Pats
No. of CR.PR
ORR (95% CI)
Fisher.exact.p.val
Overall
115
38
33% (25% - 42%)
Disease Subtypes
0.13
Diffuse Large B-Cell Lymphoma
92
27
29% (20% - 40%)
Transformed follicular lymphoma
21
10
48% (26% - 70%)
Molecular Subtypes
0.42
activated B-cell (ABC)
49
18
37% (23% - 52%)
germinal center (GC)
63
18
29% (18% - 41%)
CD19 Expression
1
CD19.No.Low
30
9
30% (15% - 49%)
CD19.POS
62
20
32% (21% - 45%)
C-Myc by IHC
0.02
Negative
38
18
47% (31% - 64%)
Positive
73
18
25% (15% - 36%)
MYC/BCL2/BCL6 Rearrangement
0.07
Double/Triple hits
20
3
15% (3% - 38%)
Negative/Not Done
91
34
37% (27% - 48%)
MYC/BCL2/BCL6 Rearrangement
0.05
Double/Triple hits
20
3
15% (3% - 38%)
Negative
52
16
31% (19% - 45%)
Not Done
39
18
46% (30% - 63%)
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1

FIG. 6



SuDHL6
E:T: Effector (T cell) to Target Ratio
UTD: Untransduced T cells
CART19: CAR-T cells
100
50
0
-50
% Killing
UTD
CART19
1
10
100
E:T

FIG. 7



SuDHL6 and Bcl2i
% Killing
E:T
UTD DMSO
CART19 DMSO
UTD Bcl2i 30nM
CART19 Bcl2i 30nM
UTD Bcl2i 100nM
CART19 Bcl2i 100nM
UTD Bcl2i 300nM
CART19 Bcl2i 300nM

FIG. 8



1500
1000
500
0
Tumor Volume (mm3)
11
14
17
19
21
24
26
28
Days Post Implant

FIG. 9



PBS
Vehicle
BCL2 inhibitor
Tumor Volume (mm3)
Day
0
1000
2000
3000
4000
0
10
20
30
40
50

FIG. 10A



UTD
Vehicle
BCL2 inhibitor
Tumor Volume (mm3)
Day
0
1000
2000
3000
4000
0
10
20
30
40
50

FIG. 10B



BCL2 inhibitor
Vehicle
CART19
Tumor Volume (mm3)
Day
0
1000
2000
3000
4000
10
20
30
40
50

FIG. 10C



D10 UTD+Venetoclax
# of cells per 20ul
100000
10000
1000
100
10
1
0
1
2
3
4
5
Week
D10 UTD+Vehicle
# of cells per 20ul
100000
10000
1000
100
10
1
0
1
2
3
4
Week

FIG. 11A



D10 CART19+Vehicle
D10 CART19+Venetoclax
# of cells per 20ul
Week
100000
10000
1000
100
10
1
0
1
2
3
4
5

FIG. 11B



D10 UTD+Vehicle
D10 UTD+Venetoclax
D10 CART19+Vehicle
D10 CART19+Venetoclax
CD3+ counts
# of cells per 20ul
100000
10000
1000
100
10
1
0
1
2
3
4
5
Week

FIG. 11C



Duration of Response by Percentage of CD3+ T cells
%CD3+ cells
≤3%
>3%
Probability of maintaining response, %
1.00
0.75
0.50
0.25
0.00
p = 0.25
0 3 6 9 12 15 18 21 24 27 30 33 36 39
Time since infusion, mo
Number at Risk
≤3% 5 3 2 2 2 2 2 1 1 1 1 1 1 1
>3% 38 26 22 21 19 17 15 14 14 14 14 12 3 0

FIG. 13A



Progression-Free Survival by Percentage of CD3+ T cells
%CD3+ cells ≤3% >3%
Probability of PFS, %
1.00
0.75
0.50
0.25
0.00
Events, n
Median (95% CI)
<3% (n=16) 13 2.2 (0.92-2.8)
≥3% (n=64) 35 4.2 (2.6-21)
p = 0.022
0 3 6 9 12 15 18 21 24 27 30 33 36 39
Time since infusion, mo
Number at Risk
≤3% 16 3 2 2 2 2 2 2 1 1 1 1 1 1
>3% 64 30 24 23 19 19 18 14 14 14 14 14 6 0

FIG. 13B



Overall Survival by Percentage of CD3+ T cells
%CD3+ cells
≤3%
>3%
Events, n
Median (95% CI)
<3% (n=16)
13
7 (1.8-12)
≥3% (n=64)
34
21 (6.7-NA)
Probability of survival, %
1.00
0.75
0.50
0.25
0.00
p = 0.032
0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48
Time since infusion, mo
Number at Risk
≤3% 16 11 8 8 4 4 4 4 4 4 3 3 3 2 0 0 0
>3% 64 54 41 36 34 30 29 27 26 26 24 24 22 12 7 4 1

FIG. 13C



Subgroup Analysis of M3 Response by Baseline Variables
Subgroups for RSPM3
No. of Pats
No. of CR.PR
ORR (95% CI)
Fisher exact p.val
Overall 115 43 37% (29% - 47%)
Disease Subtypes 0.14
Diffuse Large B-Cell Lymphoma 92 31 34% (24% - 44%)
Transformed follicular Lymphoma 21 11 52% (30% - 74%)
Molecular Subtypes 0.44
activated B-cell (ABC) 49 20 41% (27% - 56%)
germinal center (GC) 63 21 33% (22% - 46%)
CD19 Expression 0.49
CD19.No.Low 30 9 30% (15% - 49%)
CD19.Pos 62 24 39% (27% - 52%)
C-Myc by IHC 0.06
Negative 38 19 50% (33% - 67%)
Positive 73 22 30% (20% - 42%)
MYC/BCL2/BCL6 Rearrangement 0.08
Myc(-)/NoDBTPHit 89 38 43% (32% - 54%)
Myc+;DBTPHit 20 4 20% (6% - 44%)
MYC/BCL2/BCL6 Rearrangement 0.08
Myc Negative 38 19 50% (33% - 67%)
Myc+;NoDBTPHit 50 18 36% (23% - 51%)
Myc+;DBTPHit 20 4 20% (6% - 44%)
Age 0.01
< 40 years 17 1 6% (0% - 29%)
>=40 years to <65 years 72 29 40% (29% - 53%)
>=65 years 26 13 50% (30% - 70%)
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1

FIG. 14



Duration of Response by Percentage of LAG3+CD3+ T cells
%CD3+LAG3+ cells
≤20%
>20%
Probability of maintaining response, %
1.00
0.75
0.50
0.25
0.00
p = 0.0029
0 3 6 9 12 15 18 21 24 27 30 33 36 39
Time since infusion, mo
Number at Risk
≤20% 39 28 24 23 21 19 17 15 15 15 15 13 4 1
>20% 4 1 0 0 0 0 0 0 0 0 0 0 0 0

FIG. 15A



Progression-Free Survival by Percentage of LAG3+CD3+ T cells
%CD3+LAG3+ cells
≤20%
>20%
Events, n
Median (95% CI)
≤20% (n=68)
38
4.2 (2.4-21)
>20% (n=12)
10
21 (0.82-3.1)
Probability of PFS, %
1.00
0.75
0.50
0.25
0.00
p = 0.0073
0 3 6 9 12 15 18 21 24 27 30 33 36 39
Time since infusion, mo
Number at Risk
≤20% 68 30 26 25 21 21 20 16 15 15 15 15 7 1
>20% 12 3 0 0 0 0 0 0 0 0 0 0 0 0

FIG. 15B



Overall Survival by Percentage of LAG3+CD3+ T cells
%CD3+LAG3+ cells
≤20%
>20%
Events, n
Median (95% CI)
≤20% (n=68)
36
21 (10-NA)
>20% (n=12)
11
4.3 (2.7-10)
Probability of survival, %
1.00
0.75
0.50
0.25
0.00
p = 0.0062
0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48
Time since infusion, mo
Number at Risk
≤20% 68 55 45 40 36 32 31 29 28 28 26 26 24 13 6 4 1
>20% 12 10 4 4 2 2 2 2 2 2 1 1 1 1 1 0 0

FIG. 15C



Probability of PFS, %
100
90
80
70
60
50
40
30
20
10
0
Censoring Times
CR at Month 3 (n/N = 9/37)
CR at Month 6 (n/N = 6/34)
Overall (n/N = 71/115)
Kaplan – Meier medians
CR at Month 3
NE, 95% CI NE
CR at Month 6
NE, 95% CI NE
Overall
2.92 months, 95% CI (2.33 -5.16)
Number of relapses in patients with CR at 6 months
Relapse after 6 months
3
Relapse after 12 months
1
0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48
Time (months)
Number of patients still at risk
CR at Month 3 37 37 33 31 26 26 25 21 20 17 17 17 7 2 1 0
CR at Month 6 34 34 33 32 27 27 26 22 21 18 18 18 8 2 1 0
Overall 115 47 38 36 31 31 30 26 24 21 21 21 11 2 1 0

FIG. 16



Percentage of MDSCs in Baseline Biopsy
by M3 Response
CR PR SD PD Unknown
% CD11b+ out of All Cells
50
40
30
20
10
5
1
0
0
1
5
10
20
30
40
50
% CD11b+HLADR- out of All Cells

FIG. 17A



Percentage of MDSCs in Baseline Biopsy
by M9 Response
CR PR PD Unknown
Biopsy
collected
on day -855
% CD11b+ out of All Cells
% CD11b+HLADR- out of All Cells
0
1
5
10
20
30
40
50

FIG. 17B




1
LDH.3grp.Pre-infusion
p = 0.002
Normal
1-2xULN, >2xULN
2
Myc
p = 0.002
Positive
Negative
Node 3 (n = 16)
Node 4 (n = 33)
Node 5 (n = 55)
Probability of PFS, %
Months
0
10
20
30
40
20
40
60
80
100

FIG. 18



Outcome	N=115
ORR, n (%)	61 (53.0)
CR, n (%)	45 (39.1)
PR, n (%)	16 (13.9)

Relapse-free probability, %	All patients N=115	CR at Month 3 n=37	CR at Month 6 n=34
Month 24	60.4 (46.1, 72.0)	78.8 (60.3, 89.4)	86.5 (67.7, 94.7)
Month 42	60.4 (46.1, 72.0)	70.8 (60.3, 89.4)	86.5 (67.7, 94.7)

FIG. 19



Probability of Survival, %
100
90
80
70
60
50
40
30
20
10
0
Censoring times
All patients (N=115)
Number of Evens (n)
All patients: 70
Kaplan-Meier medians
All patients: 11.1 months, 95% CI (6.6-23.9)
0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 51
Time (months)
Number of Patients Still at Risk
All patients 115 93 68 59 51 47 46 44 41 38 35 34 30 19 10 3 0 0 0

FIG. 20



CD19+ B Cells by M3 Response
Progression or Post Progression*
CR/PR
SD/PD/Unknown
CD19+ (cells/uL)
1000
100
10
1
0.1
0
500
1000
1500
-100
0
100
200
300
400
Days (Infusion Days = 1)

FIG. 21



Percentage of CD3+ T cells by Month 3 Response
90
80
70
60
50
40
30
20
10
1
0.1
0
CD3+ T cells, %
p = 0.11
CR/PR (n=31)
NR (n=49)
Month 3 Response

FIG. 22



Percentage of LAG3+CD3+ T cells by Month 3 Response
p = 0.67
60
40
20
0
LAG3+CD3+ T cells, %
Turned to PD
on day 157
CR/PR (n=31)
NR (n=49)
Month 3 Response

FIG. 23



CR
PR
PD
Unknown
Proportion
1.00
0.75
0.50
0.25
0
C0
C1
C2
C3
C4
C5
n=2
n=2
n=18
n=12
n=3
n=9
Chapuy
BN2
EZB
MCD
N1
UNK
n=11
n=17
n=3
n=14
n=1
Schmitz

FIG. 24